| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | X4 Pharmaceuticals, Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 13.05. | X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference | 1 | GlobeNewswire (USA) | ||
| 09.05. | X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility | 5 | GlobeNewswire (USA) | ||
| 07.05. | Earnings call: X4 Pharmaceuticals reports Q1 2024 results and drug developments | 1 | Investing.com | ||
| 07.05. | X4 Pharmaceuticals, Inc - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 07.05. | X4 Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary | 1 | Reuters | ||
| 07.05. | X4 Pharmaceuticals, Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 07.05. | X4 Pharmaceuticals GAAP EPS of -$0.26 | 2 | Seeking Alpha | ||
| 07.05. | X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates | 53 | GlobeNewswire (Europe) | U.S. launch underway for XOLREMDI (mavorixafor) in WHIM syndrome XOLREMDI Phase 3 4WHIM clinical trial data published online in Blood, the journal of the American Society of Hematology ... ► Artikel lesen | |
| 01.05. | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 51 | GlobeNewswire (Europe) | BOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective... ► Artikel lesen | |
| 30.04. | FDA approves X4 Pharmaceuticals' WHIM syndrome drug | 4 | Pharmaceutical Technology | ||
| 29.04. | FDA Approves X4 Pharmaceuticals' Mavorixafor As First Therapy For Rare Immunodeficiency Disorder | 2 | Benzinga.com | ||
| 29.04. | US FDA approves X4 Pharmaceuticals' therapy for immunodeficiency disease | 3 | Reuters | ||
| 29.04. | X4 Pharmaceuticals Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome | 245 | GlobeNewswire (Europe) | XOLREMDI targets CXCR4 pathway dysfunction, the underlying cause of WHIM syndrome Breakthrough Therapy approval follows Priority Review of 4WHIM Phase 3 clinical trial data X4 granted Rare Pediatric... ► Artikel lesen | |
| 29.04. | X4 Pharmaceuticals, Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 02.04. | X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 88 | GlobeNewswire (Europe) | BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective... ► Artikel lesen | |
| 01.04. | X4 Pharmaceuticals, Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 01.04. | X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences | 1 | GlobeNewswire (USA) | ||
| 22.03. | X4 Pharmaceuticals, Inc. (XFOR) Q4 2023 Earnings Call Transcript | 3 | Insider Monkey | ||
| 21.03. | X4 Pharmaceuticals, Inc - 10-K, Annual Report | 1 | SEC Filings |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NEL | 3.121 |
| GAMESTOP | 2.977 |
| NVIDIA | 2.709 |
| EVOTEC | 2.461 |
| TUI | 1.577 |
| BAYER | 1.360 |
| BIONTECH | 1.038 |
| PLUG POWER | 901 |
| RHEINMETALL | 821 |
| DEUTSCHE LUFTHANSA | 713 |
| VOLKSWAGEN | 712 |
| BYD | 667 |
| SUPER MICRO COMPUTER | 665 |
| SIEMENS ENERGY | 660 |
| MERCEDES-BENZ | 593 |
| COMMERZBANK | 574 |
| TESLA | 542 |
| AIXTRON SE | 526 |
| HEIDELBERGER DRUCK | 516 |
| DEUTSCHE BANK | 504 |
| RWE | 499 |
| RENK GROUP | 477 |
| AMC ENTERTAINMENT | 460 |
| BASF | 458 |
| ADLER GROUP | 438 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
